Quantcast

ChromaDex Licenses Nicotinamide Riboside Technology from Cornell University

July 13, 2011

IRVINE, Calif., July 13, 2011 /PRNewswire/ — ChromaDex Corp. (OTCBB.:CDXC) today announced that Cornell University has granted the natural products company ChromaDex exclusive worldwide rights to a novel manufacturing process for nicotinamide riboside (NR).

“Despite its potential to deliver significant health benefits, nicotinamide riboside, or NR, is currently not available to the market as a dietary ingredient,” said Frank L. Jaksch, Jr., CEO of ChromaDex. “The technology we have licensed from Cornell provides a cost-effective, commercially viable manufacturing process for NR, thereby solving the key barrier to entry. This provides ChromaDex with the opportunity to launch yet another novel, proprietary ingredient that shows great promise for health and wellness.”

NR, a recently discovered vitamin found naturally in milk, is a more potent version of the more commonly known niacin(vitamin B3). As such, this compound shows tremendous promise for human health. Like niacin, NR is a precursor to nicotinamide adenine dinucleotide (NAD), which is elevated by a calorie restricted diet. Increasing cellular NAD has demonstrated cell-protective and positive metabolic effects. In laboratory tests, NR has shown promise for improving cardiovascular health, glucose levels and cognitive function and has demonstrated evidence of anti-ageing effects.

“We chose NR as a largely unevaluated molecule for the purpose of enhancing cellular NAD levels, and our published scientific work has verified that NR is perhaps the most potent NAD enhancing agent ever identified,” said Dr. Anthony Sauve, Associate Professor of Pharmacology at Weill Cornell Medical College and a leading expert in NAD metabolism and NAD signaling enzymes such as sirtuins. “I am pleased that NR will be more widely available so that its properties as a pro-health substance can be more fully appreciated.”

To facilitate commercialization of NR, Dr. Sauve developed the most efficient synthesis of this compound available, and this synthesis enables large quantities of NR to be produced for a variety of potential uses.

About ChromaDex

ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.

ChromaDex Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com

ChromaDex Contact:
Laura Carney
Administrative Assistant
949-419-0288
laurac@chromadex.com

SOURCE ChromaDex Corp.


Source: newswire



comments powered by Disqus